Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.
Under the terms of the collaboration, Ablynx will provide access to novel Nanobodies against a specific, undisclosed target and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially with the option for extension thereafter. No further terms have been disclosed.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Virulence_factors
Why antidepressants don't work for so many - Northwestern research finds drugs aim at wrong target
Epidermolytic_hyperkeratosis
Brodmann_area_28
Dihybrid_cross
ProteoNic and Fraunhofer IME sign Research License and start collaboration on protein expression in plants
Beckman Coulter to Acquire Diagnostic Systems Laboratories, Inc. - Company Seeks to Gain Leadership in Specialty Endocrine Testing
QIAGEN completes second U.S. submission for companion diagnostic to guide treatment decisions in colorectal cancer
